MLchartDataset catalogue

anti-RANKL monoclonal antibody GB-223

Term · Oncology and biomedicine · MLC-T-ONC-011068

A monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with potential antiosteoclast and antineoplastic activities. Upon administration, anti-RANKL monoclonal antibody GB-223 specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces. This results in the inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. By blocking the activation of the RANK/RANKL-mediated signaling pathway, GB-223 may also reduce tumor-associated bone destruction and may result in tumor regression in bone tumors with high RANK and RANKL expressions. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation. Both RANKL and RANK are overexpressed in certain bone tumors, and the RANK/RANKL-mediated signaling pathway plays an important role in certain bone tumors.

Table 1. Record
IdentifierMLC-T-ONC-011068
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-011068",
  "term": "anti-RANKL monoclonal antibody GB-223",
  "field": "Oncology and biomedicine",
  "definition": "A monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with potential antiosteoclast and antineoplastic activities. Upon administration, anti-RANKL monoclonal antibody GB-223 specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces. This results in the inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. By blocking the activation of the RANK/RANKL-mediated signaling pathway, GB-223 may also reduce tumor-associated bone destruction and may result in tumor regression in bone tumors with high RANK and RANKL expressions. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation. Both RANKL and RANK are overexpressed in certain bone tumors, and the RANK/RANKL-mediated signaling pathway plays an important role in certain bone tumors.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-rankl-monoclonal-antibody-gb-223/"
}

Record 2,201 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.